PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 8, 2024Pharmaceuticals55 citationsOpen Access

Pharmacokinetics, Pharmacodynamics, and Side Effects of Midazolam: A Review and Case Example

JPJens‐Uwe PeterPDP DieudonnéOZOliver Zolk

Key Points

Key points are not available for this paper at this time.

Abstract

Midazolam, a short-acting benzodiazepine, is widely used to alleviate patient anxiety, enhance compliance, and aid in anesthesia. While its side effects are typically dose-dependent and manageable with vigilant perioperative monitoring, serious cardiorespiratory complications, including fatalities and permanent neurological impairment, have been documented. Prolonged exposure to benzodiazepines, such as midazolam, has been associated with neurological changes in infants. Despite attempts to employ therapeutic drug monitoring for optimal sedation dosing, its efficacy has been limited. Consequently, efforts are underway to identify alternative predictive markers to guide individualized dosing and mitigate adverse effects. Understanding these factors is crucial for determining midazolam's suitability for future administration, particularly after a severe adverse reaction. This article aims to elucidate the factors influencing midazolam's pharmacokinetics and pharmacodynamics, potentially leading to adverse events. Finally, a case study is presented to exemplify the complex investigation into the causative factors of midazolam-related adverse events.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Peter et al. (2024) studied this question.

synapsesocial.com/papers/6a00644eb124fe581985dd30https://doi.org/10.3390/ph17040473
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1MicroRNAs Regulate Human Hepatocyte Nuclear Factor 4α, Modulating the Expression of Metabolic Enzymes and Cell Cycle2009 · 150 citations
  2. 2Inflammatory response: an unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapy2003 · 226 citations
  3. 3Sex Differences in UDP-Glucuronosyltransferase 2B17 Expression and Activity2010 · 78 citations
  4. 4The effects of the SLCO2B1 c.1457C>T polymorphism and apple juice on the pharmacokinetics of fexofenadine and midazolam in humans2010 · 182 citations
  5. 5Sex-Dependent Differences in Cytochrome P450 3A Activity as Assessed by Midazolam Disposition in Humans: A Meta-Analysis2010 · 51 citations